Unstudied tendencies of clinical effectiveness of Tadalafil in men with erectile dysfunction and chronic non-inflammatory prostatitis
A.O. LOBKAREV, R.KH. KHAFIZYANOVA, O.A. LOBKAREV
Clinic of Ambulatory Urology, 12 Kamaleeva Ave., Kazan, Russian Federation, 420081
Lobkarev A.O. — Ph. D (medicine), tel. +7 (843) 258-98-73, e-mail: [email protected], ORCID ID: 0000-0002-6618-4792
Khafizyanova R.Kh. — D. Sc. (medicine), Professor, tel. +7 (843) 292-59-02, e-mail: [email protected], ORCID ID: 0000-0002-3906-3661
Lobkarev O.A. — D. Sc. (medicine), Professor, tel. +7 (843) 222-52-31, e-mail: [email protected], ORCID ID: 0000-0001-5223-4261
To study the changes of the Clinical Index of Chronic Prostatitis (CI-CP) and the International Index of Erectile Function (IIEF-5) during Tadalafil intake 5 mg once daily as monotherapy in men with erectile dysfunction (ED) in combination with chronic non-inflammatory prostatitis (CNIP).
Material and methods. The data from outpatient records of 88 patients diagnosed with «Chronic non-inflammatory prostatitis. Erectile dysfunction», treated in the Clinic of Ambulatory Urology (Kazan) in the period from 2012 to 2017, were studied. The following indicators were analyzed: CI-CP before the start of pharmacotherapy, as well as 28 days after the start of pharmacotherapy; IIEF-5) before the start of pharmacotherapy, as well as 28 days after the start of pharmacotherapy. Based on these indicators, discrete variation series were built, respectively, for CI-CP, containing integer values from 0 points (no complaints) to 50 points (maximum points = most pronounced symptoms), and for IIEF, containing values from 0 points (maximum degree of ED) to 25 points (normal = no ED).
The conclusions. Tadalafil at a dose of 5 mg per day leads to a statistically significant improvement in the International Index of Erectile Function (p<0.05). But the clinical efficacy of Tadalafil, calculated on the «Clinical Index of Chronic Prostatitis», is multivalued.
Key words: Tadalafil, chronic prostatitis, erectile dysfunction, pharmacotherapy.
(For citation: Lobkarev A.O., Khafizyanova R.Kh., Lobkarev O.A. Unstudied tendencies of clinical effectiveness of Tadalafil in men with erectile dysfunction and chronic non-inflammatory prostatitis. Practical Medicine. 2018)
REFERENCES
- Medik V.A., Tokmachev M.S., Fishman B.B. Statistika v meditsine i biologii. V 2-kh t. T.1 [Statistics in medicine and biology. In 2 volumes. Volume 1]. Moscow: Meditsina, 2000. 412 p.
- Zaytsev V.M., Liflyandskiy V.G., Marinkin V.I. Prikladnaya meditsinskaya statistika [Applied medical statistics]. Saint Petersburg: FOLIANT, 2003. 432 p.
- Brock G.B., McMahon C.G., Chen K.K. et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. Journal of Urology, 2002, no. 10, pp. 1332–1336.
- Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. International Journal of Clinical Practice, 2002, no. 6, pp. 453–459.
- Eardley I., Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. International Journal of Clinical Practice, 2002, no. 4, pp. 300–304.
- Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Natural Review of Drug Discovery, 2002, no. 9, pp. 674–682.
- Yuan J.Q., Mao C., Wong S.Y. et al. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine, 2015, no. 7, pp. 415–422.
- Hayashi K., Fukagai T., Koshikiya A. et al. Effect of tadalfil that was additionally administered to patients receiving an alpha1-blocker in Japanese men with lower urinary thact symptoms suggestive of benign prostatic hyperplasia. Nihon Hinyokika Gakkai Zasshi, 2016, no. 1, pp. 28–33.
- Eardley I. Does it matter how tadalafil improves lower urinary tract symptoms? European Urology, 2015, no. 1, pp. 123–124.
- Balhara Y.P., Sarkar S., Gupta R. Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Endocrinology and Metabolism, 2015, no. 4, pp. 451–461.
- Hakky T.S., Jain L. Current use of phosphodiesterase inhibitors in urology. Turkish Journal of Urology, 2015, no. 1, pp. 88–92.
- Urologiya: natsionalʹnoe rukovodstvo, pod red. N.A. Lopatkina [Urology: national leadership. Ed. by N.A. Lopatkin]. Moscow: GEHOTAR-Media, 2009. 1024 p.
- Integrativnaya urologiya. Rukovodstvo dlya vrachey, pod red. P.V. Glybochko, Yu.G. Alyaeva [Integrative urology. Guide for doctors. Ed. by P.V. Glybochko, Yu.G. Alyaev]. Moscow: Medforum, 2014. 432 p.
- Loran O.B., Segal A.S. System of total assessment of symptoms in chronic prostatitis. Urologiya, 2001, no. 5, pp. 16–19 (in Russ.).
- Rosen R.C., Cappelleri J.C., Smith M.D., Lipsky J., Pena B.M. Constructing and evaluating the «Sexual Health Inventory for Men: IIEF-5» as a diagnostic tool for erectile dysfunction (ED). International Journal of Impotence Research, 1998, no. 10, no. S3–S35.
- Khafizʹyanova R.Kh., Burykin I.M., Aleeva G.N. Matematicheskaya statistika v ehksperimentalʹnoy i klinicheskoy farmakologii [Mathematical statistics in experimental and clinical pharmacology]. Kazan: Meditsina, 2006. Pp. 102–104.